CLAIMS:

1. Use of an antagonist that inhibits c-met signaling activity of a human hyperstabilized c-met polypeptide, wherein the hyperstabilized c-met polypeptide comprises an in-frame deletion of exon 14, the deletion removing the Y1003 phosphorylation site, such that degradation of the polypeptide is diminished compared to wild type c-met, and wherein the hyperstabilized c-met polypeptide has c-met signaling activity, for the manufacture of a medicament for treating a tumor comprising hyperstabilized c-met in a subject, said medicament is to be administered to a subject, whereby the tumor is treated, wherein the antagonist is
(i) an antibody that binds to human hyperstabilized c-met polypeptide; or
(ii) an inhibitory RNA or antisense oligonucleotide that inhibits expression from a nucleic acid molecule encoding human hyperstabilized c-met polypeptide.

2. The use according to claim 1, wherein the tumor is a lung tumor.

3. The use according to claim 2, wherein the tumor is a non-small cell lung cancer (NSCLC) tumor.

4. The use according to claim 1, wherein inhibition of c-met signaling activity by the antagonist comprises enhancement of cellular degradation of the hyperstabilized c-met protein.

5. The use according to claim 1, wherein the antagonist is an antibody that binds to human hyperstabilized c-met polypeptide, and wherein the antagonist is linked to a toxin.

6. The use according to claim 1, wherein the antagonist is an antibody that binds to an epitope formed by in-frame splicing of exon 13 and exon 15 of human c-met.

7. The use according to claim 1, wherein the antagonist is an inhibitory RNA or an antisense oligonucleotide that preferentially inhibits expression from a nucleic acid molecule encoding a splice variant of c-met wherein exon 13 is spliced to exon 15.

8. The use according to claim 1, wherein the antagonist is an antibody which is a monoclonal antibody, antibody fragment, chimeric antibody, humanized antibody, human antibody, multi-specific antibody or single-chain antibody.

9. The use according to claim 1, wherein the antagonist is to be administered in conjunction with an agent that induces receptor protein degradation.